Page 10«..9101112..2030..»

Patient Enrollment Reaches 90 Percent in Innovation Pharmaceuticals Phase 2 Clinical Trial of Brilacidin for COVID-19

By Dr. Matthew Watson

WAKEFIELD, Mass., May 27, 2021 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today announces that patient enrollment in the Company’s 120-patient, Phase 2 clinical trial of Brilacidin for COVID-19 has reached 90 percent and that the Company anticipates full enrollment to be completed in approximately two weeks.

View post:
Patient Enrollment Reaches 90 Percent in Innovation Pharmaceuticals Phase 2 Clinical Trial of Brilacidin for COVID-19

To Read More: Patient Enrollment Reaches 90 Percent in Innovation Pharmaceuticals Phase 2 Clinical Trial of Brilacidin for COVID-19
categoriaGlobal News Feed commentoComments Off on Patient Enrollment Reaches 90 Percent in Innovation Pharmaceuticals Phase 2 Clinical Trial of Brilacidin for COVID-19 | dataMay 28th, 2021
Read All

Update – Nanox to Participate in the Jefferies Virtual Healthcare Conference

By Dr. Matthew Watson

NEVE ILAN, Israel, May 27, 2021 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (NASDAQ: NNOX) (“Nanox” or the “Company”), an innovative medical imaging technology company, today announces that Nanox’s Chairman and Chief Executive Officer Ran Poliakine will make a company presentation and the leadership team will host investor 1x1 meetings during the Jefferies Virtual Healthcare Conference, which is being held June 1st through June 4th.

Link:
Update – Nanox to Participate in the Jefferies Virtual Healthcare Conference

To Read More: Update – Nanox to Participate in the Jefferies Virtual Healthcare Conference
categoriaGlobal News Feed commentoComments Off on Update – Nanox to Participate in the Jefferies Virtual Healthcare Conference | dataMay 28th, 2021
Read All

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)

By Dr. Matthew Watson

ORION CORPORATION STOCK EXCHANGE RELEASE / MAJOR SHAREHOLDER ANNOUNCEMENTS27 MAY 2021 at 18.50 EEST

Read this article:
Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)

To Read More: Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)
categoriaGlobal News Feed commentoComments Off on Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.) | dataMay 28th, 2021
Read All

Kane Biotech Announces First Quarter 2021 Financial Results

By Dr. Matthew Watson

WINNIPEG, Manitoba, May 27, 2021 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”), today announced first quarter 2021 financial results.

Visit link:
Kane Biotech Announces First Quarter 2021 Financial Results

To Read More: Kane Biotech Announces First Quarter 2021 Financial Results
categoriaGlobal News Feed commentoComments Off on Kane Biotech Announces First Quarter 2021 Financial Results | dataMay 28th, 2021
Read All

OSE Immunotherapeutics and the FoRT Foundation Announce Initiation of a Phase 2 Clinical Trial Evaluating Tedopi® in Combination with Opdivo®…

By Dr. Matthew Watson

NANTES, France and ROME, May 27, 2021 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics (ISIN: FR0012127173; Mnemo: OSE) and the FoRT Foundation (Fondazione Ricerca Traslazionale) today announced that the Italian Medicines Agency (AIFA) and the Italian Ethics Committee approved the initiation of a new Phase 2 clinical trial evaluating Tedopi® in combination with Opdivo® or chemotherapy as second-line treatment in patients with metastatic non-small cell lung cancer (NSCLC).

Go here to see the original:
OSE Immunotherapeutics and the FoRT Foundation Announce Initiation of a Phase 2 Clinical Trial Evaluating Tedopi® in Combination with Opdivo®...

To Read More: OSE Immunotherapeutics and the FoRT Foundation Announce Initiation of a Phase 2 Clinical Trial Evaluating Tedopi® in Combination with Opdivo®…
categoriaGlobal News Feed commentoComments Off on OSE Immunotherapeutics and the FoRT Foundation Announce Initiation of a Phase 2 Clinical Trial Evaluating Tedopi® in Combination with Opdivo®… | dataMay 28th, 2021
Read All

Galapagos to present data on rheumatoid arthritis at the upcoming European League Against Rheumatism (EULAR) congress

By Dr. Matthew Watson

Mechelen, Belgium, 27 May 2021, 22:01 CET, – Galapagos NV (Euronext & Nasdaq: GLPG) today announced that 15 abstracts, including scientific updates, and data providing further understanding on the profile of filgotinib as a treatment for people with Rheumatoid Arthritis (RA), will be presented at the European League Against Rheumatism (EULAR) virtual congress 2021, 2-5 June.

Link:
Galapagos to present data on rheumatoid arthritis at the upcoming European League Against Rheumatism (EULAR) congress

To Read More: Galapagos to present data on rheumatoid arthritis at the upcoming European League Against Rheumatism (EULAR) congress
categoriaGlobal News Feed commentoComments Off on Galapagos to present data on rheumatoid arthritis at the upcoming European League Against Rheumatism (EULAR) congress | dataMay 28th, 2021
Read All

Ascendis Pharma A/S Reports First Quarter 2021 Financial Results

By Dr. Matthew Watson

– Pre-launch activities continue in preparation for a potential FDA approval of TransCon™ hGH (lonapegsomatropin) for pediatric growth hormone deficiency; PDUFA date of June 25, 2021 –

Link:
Ascendis Pharma A/S Reports First Quarter 2021 Financial Results

To Read More: Ascendis Pharma A/S Reports First Quarter 2021 Financial Results
categoriaGlobal News Feed commentoComments Off on Ascendis Pharma A/S Reports First Quarter 2021 Financial Results | dataMay 28th, 2021
Read All

Biomea Fusion Reports First Quarter 2021 Financial Results and Business Highlights

By Dr. Matthew Watson

-- Received $167 million in aggregate gross proceeds in April from initial public offering --– Advancing lead oncology program BMF-219, a small molecule irreversible menin inhibitor, toward IND filing in second half of 2021 --

Read the rest here:
Biomea Fusion Reports First Quarter 2021 Financial Results and Business Highlights

To Read More: Biomea Fusion Reports First Quarter 2021 Financial Results and Business Highlights
categoriaGlobal News Feed commentoComments Off on Biomea Fusion Reports First Quarter 2021 Financial Results and Business Highlights | dataMay 28th, 2021
Read All

Vaxcyte to Present at the Jefferies Virtual Healthcare Conference

By Dr. Matthew Watson

FOSTER CITY, Calif., May 27, 2021 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide, today announced that Company management will present at the Jefferies Virtual Healthcare Conference on Thursday, June 3, 2021 at 4:00pm ET.

Continued here:
Vaxcyte to Present at the Jefferies Virtual Healthcare Conference

To Read More: Vaxcyte to Present at the Jefferies Virtual Healthcare Conference
categoriaGlobal News Feed commentoComments Off on Vaxcyte to Present at the Jefferies Virtual Healthcare Conference | dataMay 28th, 2021
Read All

Chiasma Presents Positive Patient-Reported Outcomes Data from its MPOWERED™ Phase 3 Trial Comparing MYCAPSSA® to Long-Acting Injectables for the…

By Dr. Matthew Watson

--Data presented at AACE 2021 demonstrate patient quality of life and work productivity significantly improved in patients transitioning from injectable SSAs to MYCAPSSA®-- --Data presented at AACE 2021 demonstrate patient quality of life and work productivity significantly improved in patients transitioning from injectable SSAs to MYCAPSSA®--

Read more:
Chiasma Presents Positive Patient-Reported Outcomes Data from its MPOWERED™ Phase 3 Trial Comparing MYCAPSSA® to Long-Acting Injectables for the...

To Read More: Chiasma Presents Positive Patient-Reported Outcomes Data from its MPOWERED™ Phase 3 Trial Comparing MYCAPSSA® to Long-Acting Injectables for the…
categoriaGlobal News Feed commentoComments Off on Chiasma Presents Positive Patient-Reported Outcomes Data from its MPOWERED™ Phase 3 Trial Comparing MYCAPSSA® to Long-Acting Injectables for the… | dataMay 28th, 2021
Read All

AnaptysBio to Present at the 2021 Jefferies Virtual Healthcare Conference

By Dr. Matthew Watson

SAN DIEGO, May 27, 2021 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, today announced that Hamza Suria, chief executive officer of AnaptysBio, will present at the Jefferies Virtual Healthcare Conference on Thursday, June 3, 2021 at 1:30 p.m. ET. The conference will be conducted virtually, and the audio presentation will be available via: https://wsw.com/webcast/jeff174/anab/1811646.

See more here:
AnaptysBio to Present at the 2021 Jefferies Virtual Healthcare Conference

To Read More: AnaptysBio to Present at the 2021 Jefferies Virtual Healthcare Conference
categoriaGlobal News Feed commentoComments Off on AnaptysBio to Present at the 2021 Jefferies Virtual Healthcare Conference | dataMay 28th, 2021
Read All

GENFIT Informs its Shareholders of Certain Procedures for the Combined General Meeting of June 15, 2021

By Dr. Matthew Watson

Lille, France; Cambridge, MA; May 27, 2021 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and liver diseases (the “Company”), today informs its shareholders of certain participation and organization procedures for the ordinary and extraordinary general meeting of June 15, 2021 (the “Combined General Meeting”) in accordance with decree n°2021-255 of March 9, 2021, extending the application of measures of ordinance n°2020-321 of March 25, 2020 and its application decree n°2020-418 of April 10, 2020 which was extended until July 31, 2021 by the decree n°2021-255 of March 9, 2021 (the “Decree”).

See the original post:
GENFIT Informs its Shareholders of Certain Procedures for the Combined General Meeting of June 15, 2021

To Read More: GENFIT Informs its Shareholders of Certain Procedures for the Combined General Meeting of June 15, 2021
categoriaGlobal News Feed commentoComments Off on GENFIT Informs its Shareholders of Certain Procedures for the Combined General Meeting of June 15, 2021 | dataMay 28th, 2021
Read All

LIDDS intends to carry out a directed share issue of approximately MSEK 45

By Dr. Matthew Watson

NOT FOR DISTRIBUTION DIRECTLY OR INDIRECTLY, WITHIN OR INTO AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA OR THE UNITED STATES, OR IN ANY OTHER JURISDICTION WHERE THE DISTRIBUTION OF THIS PRESS RELEASE WOULD BE IN VIOLATION OF APPLICABLE RULES OR REQUIRE REGISTRATION OR OTHER MEASURES.

Follow this link:
LIDDS intends to carry out a directed share issue of approximately MSEK 45

To Read More: LIDDS intends to carry out a directed share issue of approximately MSEK 45
categoriaGlobal News Feed commentoComments Off on LIDDS intends to carry out a directed share issue of approximately MSEK 45 | dataMay 28th, 2021
Read All

Immunocore to present at upcoming investor conferences

By Dr. Matthew Watson

PRESS RELEASE

Read the rest here:
Immunocore to present at upcoming investor conferences

To Read More: Immunocore to present at upcoming investor conferences
categoriaGlobal News Feed commentoComments Off on Immunocore to present at upcoming investor conferences | dataMay 28th, 2021
Read All

MDxHealth Announces Results of its Annual and Extraordinary General Shareholders’ Meetings

By Dr. Matthew Watson

NEWS RELEASE – REGULATED INFORMATION

See the original post here:
MDxHealth Announces Results of its Annual and Extraordinary General Shareholders’ Meetings

To Read More: MDxHealth Announces Results of its Annual and Extraordinary General Shareholders’ Meetings
categoriaGlobal News Feed commentoComments Off on MDxHealth Announces Results of its Annual and Extraordinary General Shareholders’ Meetings | dataMay 28th, 2021
Read All

Travere Therapeutics to Present at Upcoming Investor Conferences

By Dr. Matthew Watson

SAN DIEGO, May 27, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that Company management will present at the following upcoming virtual investor conferences in June:

Read this article:
Travere Therapeutics to Present at Upcoming Investor Conferences

To Read More: Travere Therapeutics to Present at Upcoming Investor Conferences
categoriaGlobal News Feed commentoComments Off on Travere Therapeutics to Present at Upcoming Investor Conferences | dataMay 28th, 2021
Read All

Cyclerion Therapeutics Announces Publication of CY6463 Preclinical Data in Frontiers in Pharmacology

By Dr. Matthew Watson

Series of preclinical studies demonstrate the therapeutic potential of CY6463, a first-in-class, CNS-penetrant sGC stimulator

Go here to read the rest:
Cyclerion Therapeutics Announces Publication of CY6463 Preclinical Data in Frontiers in Pharmacology

To Read More: Cyclerion Therapeutics Announces Publication of CY6463 Preclinical Data in Frontiers in Pharmacology
categoriaGlobal News Feed commentoComments Off on Cyclerion Therapeutics Announces Publication of CY6463 Preclinical Data in Frontiers in Pharmacology | dataMay 28th, 2021
Read All

Iterum Therapeutics Provides Update on NDA Review

By Dr. Matthew Watson

DUBLIN, Ireland and CHICAGO, May 27, 2021 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company”), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that the Company participated in a late-cycle meeting with the U.S. Food and Drug Administration (“FDA”) yesterday. During the meeting, the FDA shared issues still under review regarding the Company’s new drug application (“NDA”) for sulopenem etzadroxil/probenecid for the treatment of uncomplicated urinary tract infections in patients with a quinolone non-susceptible pathogen and the Company responded to these issues. The FDA has determined that an Advisory Committee meeting is not currently necessary. The review of the NDA is ongoing and the Company was informed that the FDA continues to work toward the PDUFA goal date of July 25, 2021.

Visit link:
Iterum Therapeutics Provides Update on NDA Review

To Read More: Iterum Therapeutics Provides Update on NDA Review
categoriaGlobal News Feed commentoComments Off on Iterum Therapeutics Provides Update on NDA Review | dataMay 28th, 2021
Read All

Medexus Announces Amendments to its Credit Agreements

By Dr. Matthew Watson

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

Continued here:
Medexus Announces Amendments to its Credit Agreements

To Read More: Medexus Announces Amendments to its Credit Agreements
categoriaGlobal News Feed commentoComments Off on Medexus Announces Amendments to its Credit Agreements | dataMay 28th, 2021
Read All

The performance of Olainfarm Group in Q1 2021 is convincingly resilient

By Dr. Matthew Watson

“We have started the year with a targeted momentum despite the impact of the Covid-19 pandemic, and this is also reflected in the company's financial results. The new marketing strategy was the driving force behind maintaining the position of our products and services in our markets. We are committed to our strategy and invest in production, product development, IT and digitalisation. Our care for patients with health problems related to pain, inflammation, cardiovascular disease, mental health and other conditions remains unchanged," said Jeroen Weites, Chairperson of the Management Board of JSC Olainfarm.

Read the rest here:
The performance of Olainfarm Group in Q1 2021 is convincingly resilient

To Read More: The performance of Olainfarm Group in Q1 2021 is convincingly resilient
categoriaGlobal News Feed commentoComments Off on The performance of Olainfarm Group in Q1 2021 is convincingly resilient | dataMay 28th, 2021
Read All

Page 10«..9101112..2030..»